Efficacy of vepostuzumab combined with R-CHOP in treatment of patients with diffuse large B-cell lymphoma

Ge Yi-wen; Xu Wen-bin; Lan Tian; Lin Jie

doi:10.3969/j.issn.1672-8157.2025.02.015

Abstract：Objective To explore the short-term efficacy of vepostuzumab combined with rituximab-cyclophosphamide,hydroxydoxorubicin,oncovin and prednisone(R-CHOP)in the treatment of patients with diffuse large B-cell lymphoma and the influencing factors of follow-up recurrence.Methods A total of 117 patients treated in Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from January 2023 to June 2024 were selected as the research subjects and divided into 2 groups.The patients in the control group(n=59)were treated with R-CHOP while those in the study group(n=58)were additional-ly treated with vepostuzumab.The clinical efficacy,immune function and adverse reactions after treatment were compared between the two groups and the influencing factors of relapse during follow-up peroid were analyzed by multivariate Logistic regression.Results The total effective rate of the study group was 86.21%,which was remarkably higher than that of the control((67.80%),χ2=5.584,P=0.018).The number of T lymphocytes,B lymphocytes,and NK cells in both groups was lower after than before treat-ment,but the decrease in the study group was smaller than that in the control(P=0.023).The incidence of side reactions showed no significant difference between the control group and the study group(32.20%vs 29.31%)(χ2=0.214,P=0.644).Pathological stage Ⅲ(OR=3.504,95%CI(1.548,7.935)),no combined medication(OR=4.783,95%CI(1.827,12.520)),ECOG PS>2 score(OR=4.121,95%CI(1.531,11.087))were the factors influencing the recurrence of diffuse large B-cell lymphoma(P=0.003,0.001,0.005).Conclusion Vipostuzumab combined with R-CHOP can achieve good short-term efficacy in the treatment of patients with diffuse large B-cell lymphoma,but there is a certain recurrence rate.Pathological stage Ⅲ,no combination of drugs,and ECOG PS>2 are factors affecting the recurrence of diffuse large B-cell lymphoma during follow-up period.